← Back to Search

Enzyme Inhibitor

Ceralasertib + Trastuzumab Deruxtecan for Solid Tumors

Phase 1

Recruiting

Led By Kanwal P Raghav

Research Sponsored by National Cancer Institute (NCI)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Must have Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1

Age >= 18 years

Must not have

Any previous treatment with an ATR inhibitor

Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Summary

This trial will find the best dose and safety of ceralasertib when given with trastuzumab deruxtecan to treat patients with solid tumors that have a change in the HER2 gene or protein.

Who is the study for?

Adults with advanced solid tumors expressing HER2, who've tried at least one chemotherapy, can join this trial. They must have a measurable tumor and be able to undergo biopsies. Key health requirements include proper liver and kidney function, controlled HIV if present, no severe heart issues or lung disease like ILD/pneumonitis, and not pregnant.Check my eligibility

What is being tested?

The DASH trial is testing the combination of two drugs: DS-8201a (trastuzumab deruxtecan) which targets HER2 cancer cells with attached chemo drug deruxtecan; and AZD6738 (ceralasertib), which may halt tumor growth by blocking certain enzymes. The study has two phases to determine safety and compare responses in colorectal/gastroesophageal cancers.See study design

What are the potential side effects?

Potential side effects include reactions related to immune system activation such as inflammation in organs or infusion-related symptoms. There might also be typical chemotherapy side effects like fatigue, nausea, blood cell count changes increasing infection risk, and potential heart or lung complications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am fully active or restricted in physically strenuous activity but can do light work.

Select...

I am 18 years old or older.

Select...

My disease cannot be removed by surgery and has spread.

Select...

I have a tumor that can be measured on a CT scan.

Select...

I have an advanced solid tumor, such as breast or colon cancer.

Select...

I agree to a biopsy of my cancer that can be easily reached.

Select...

My tumor is HER2-positive, confirmed by a certified lab.

Select...

My heart pumps well, with an ejection fraction of 50% or higher.

Select...

My cancer is confirmed to be advanced stomach, esophagus, or colorectal.

Select...

I've had chemotherapy for advanced cancer but it didn't work or I couldn't tolerate it.

Select...

I am not pregnant.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have never been treated with an ATR inhibitor.

Select...

I cannot take pills by mouth or have stomach issues that affect medication absorption.

Select...

I haven't had a heart attack in the last 6 months and my heart functions well.

Select...

I have spinal cord compression or active brain metastases.

Select...

I have lung problems due to another illness.

Select...

I am not taking strong CYP3A inhibitors.

Select...

I need treatment to remove fluid from my chest, abdomen, or around my heart.

Select...

I have taken corticosteroids within the last 2 weeks.

Select...

I do not have any unmanaged ongoing illnesses.

Select...

I am not taking chloroquine or hydroxychloroquine.

Select...

I have high blood pressure that needs treatment.

Select...

I have had a bone marrow or double umbilical cord blood transplant.

Select...

I experience significant drops in blood pressure when standing.

Select...

I have been diagnosed with MDS/AML or show signs of these conditions.

Select...

I do not have an infection that needs IV treatment.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Differential pharmacodynamic (PD) profile of tumor tissue (DNA damage & repair) (Dose expansion phase)

Incidence of adverse events (Dose escalation phase)

Recommended phase 2 dose (Dose escalation phase)

Secondary outcome measures

Anti-tumor activity of DS-8201a plus (+) AZD6738

Best overall response

Disease control rate

+7 more

Other outcome measures

Association of HER2 expression level and HER2 gene copy number and ORR

Palladium

Association of TOP1 expression level and ORR

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (trastuzumab deruxtecan, ceralasertib)Experimental Treatment8 Interventions

Patients receive trastuzumab deruxtecan IV over 30-90 minutes on day 1 and ceralasertib PO BID on days 1-7. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. NOTE: During the dose-expansion phase, the first 6 patients in each disease cohort (gastroesophageal cancer [cohort A] and colorectal cancer [cohort B]) receive only trastuzumab deruxtecan for the first cycle, followed by trastuzumab deruxtecan and ceralasertib together in subsequent cycles. Additionally, patients undergo tissue biopsy on study and blood sample collection, CT or PET/CT and ECHO or MUGA throughout the study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Biospecimen Collection

2004

Completed Phase 2

~1720

Positron Emission Tomography

2008

Completed Phase 2

~2210

Multigated Acquisition Scan

2015

Completed Phase 2

~50

Echocardiography

2013

Completed Phase 4

~11670

Computed Tomography

2017

Completed Phase 2

~2720

Biopsy

2014

Completed Phase 4

~1090

Ceralasertib

2017

Completed Phase 1

~30

Trastuzumab Deruxtecan

2021

Completed Phase 3

~610

0 / 26Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor

13,748 Previous Clinical Trials

40,959,350 Total Patients Enrolled

944 Trials studying Breast Cancer

1,544,008 Patients Enrolled for Breast Cancer

Kanwal P RaghavPrincipal InvestigatorUniversity of Texas MD Anderson Cancer Center LAO

1 Previous Clinical Trials

49 Total Patients Enrolled

Media Library

Ceralasertib (Enzyme Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04704661 — Phase 1

Breast Cancer Research Study Groups: Treatment (trastuzumab deruxtecan, ceralasertib)

Breast Cancer Clinical Trial 2023: Ceralasertib Highlights & Side Effects. Trial Name: NCT04704661 — Phase 1

Ceralasertib (Enzyme Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04704661 — Phase 1

~19 spots leftby Mar 2026

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.